Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + cadonilimab
- Development stage
- Phase 3
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of disitamab vedotin (RC48), a HER2-directed antibody-drug conjugate (ADC), and cadonilimab (AK104), a bispecific antibody targeting PD-1 and CTLA-4. Disitamab vedotin is composed of a humanized anti-HER2 antibody conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Cadonilimab is a first-in-class bispecific antibody designed to simultaneously block the PD-1 and CTLA-4 immune checkpoints, thereby enhancing T-cell mediated anti-tumor activity. The combination is being evaluated as a second-line treatment for patients with HER2-mutant advanced or metastatic bile duct adenocarcinoma in a Phase II clinical trial led by Zhejiang Cancer Hospital. The rationale for this combination is to leverage the targeted cytotoxic effects of the ADC with the dual checkpoint inhibition of the bispecific antibody to overcome resistance and improve clinical outcomes in HER2-expressing biliary tract cancers.
- Brand names
- AidexiKaitani
- Other names
- RC48 plus AK104RC-48 plus AK104RC 48 plus AK104Disitamab Vedotin Plus Cadonilimab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on disitamab vedotin + cadonilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + cadonilimab.